NCT04838652Active, not recruitingPhase 2
Pembro-CORE pilot
Pembro-CORE pilot - Phase II trial of Pembrolizumab in COmbination with salvage chemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Dec 2025
Brief summary (registry, in English)
The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). The primary objective of this prospective, multicenter phase II trial is to estimate efficacy of the novel combination therapy in the treatment of r/r cHL.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- First submitted
- 27 Feb 2023
- Start date
- 26 Jan 2024
- Lead sponsor
- University Of Cologne
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT04838652
- EU CT number
- 2022-501306-35-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 29
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or concurrent disease that prevents treatment according to protocol
- Long-term ingestion of corticosteroids or antineoplastic drugs
Other illness
- Malignant disease, other than cHL, within the last 5 years
- Subjects with active, known or suspected autoimmune diease
Lab values
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Other
- ECOG performance status ≥ 2
- Non-compliance
- Female subject is pregnant or breastfeeding
- Unsafe contraceptive methods
Who the study is looking for
- Histologically confirmed first relapse of cHL or primary refractory cHL
- No previous treatment for r/r HL
- Age: 18-65 years
- Patient has given written informed consent to participate in the trial
- Estimated life expectancy > 3 months
- In women: negative pregnancy test
- Presence of measurable disease - Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the date of enrollment
- Patient is considered to be eligible for autologous stem cell transplantation by the investigator
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Cologne AöR Coordinator of this site? Confirm its status | Cologne | Germany | Active, not recruiting |
| Universitaetsklinikum Essen (AoR) Coordinator of this site? Confirm its status | Essen | Germany | Active, not recruiting |
| University Hospital Jena KöR Coordinator of this site? Confirm its status | Jena | Germany | Active, not recruiting |
| Universitatsklinikum Wurzburg AöR Coordinator of this site? Confirm its status | Wuerzburg | Germany | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.